Drug Shortage Active
NAROPIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
NAROPIN (ropivacaine hydrochloride) by Fresenius Kabi is s-(-)-enantiomer. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 3d ago
NAROPIN (ropivacaine hydrochloride) is an S-(-)-enantiomer local anesthetic administered by injection as a solution. It blocks nerve impulse generation and conduction by increasing electrical excitation threshold, used for regional anesthesia procedures including nerve blocks and epidural anesthesia. The drug produces selective nerve blockade in a predictable sequence: pain, temperature, touch, proprioception, and skeletal muscle tone.
With LOE imminent (November 2026) and moderate competitive pressure, brand teams face significant commercial contraction requiring transition planning or focus on specialty formulations and provider relationships.
S-(-)-enantiomer. Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Antalgic Efficacy of CycloMesh™ Soaked in Ropivacaine Hydrochloride in Uncomplicated Inguinal Hernia.
Worked on NAROPIN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Roles on NAROPIN are currently limited (0 linked positions), reflecting the product's approaching loss of exclusivity and stable, mature market status. Professionals considering this product should anticipate transitional career moves focused on generic portfolio management, contracting, and healthcare provider relationships rather than brand building.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo